Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers is a research paper published in EMBO Molecular Medicine (2021). On theSindex it has a DataRank of 0.736. It has been cited 134 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.736
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →H2020 European Research Council
Grant: 949570
Knut och Alice Wallenbergs Stiftelse
Grant: 2017‐0383
Marianne and Marcus Wallenberg Foundation
Grant: 2015.0125
Parkinsonfonden
Grant: 1280/20
Vetenskapsrådet
Grant: (2016‐00906
Medical Research Council
Grant: UKDRI-1003
NIA NIH HHS
Grant: U01 AG024904
CIHR
CIHR
FWCI
13.59
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
Additional file 1 of CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
Additional file 1 of Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Additional file 1 of Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Additional file 1 of Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Additional file 1 of Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Additional file 2 of Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Additional file 2 of Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Additional file 1 of Tau modulation through AAV9 therapy augments Akt/Erk survival signalling in glaucoma mitigating the retinal degenerative phenotype
Additional file 1 of Tau modulation through AAV9 therapy augments Akt/Erk survival signalling in glaucoma mitigating the retinal degenerative phenotype